1647P Dabrafenib/trametinib versus encorafenib/binimetinib in BRAF-mutant metastatic melanoma: A real-world propensity score matched survival analysis.
Saved in:
| Title: | 1647P Dabrafenib/trametinib versus encorafenib/binimetinib in BRAF-mutant metastatic melanoma: A real-world propensity score matched survival analysis. |
|---|---|
| Authors: | Garitaonaindía Díaz, Y.1 (AUTHOR), Khan, S.1 (AUTHOR), Friis, R.B.2 (AUTHOR), Petersen, S.K.3 (AUTHOR), Borch, T.H.1 (AUTHOR), Ruhlmann, C.H.3 (AUTHOR), Guldbrandt, L.M.2 (AUTHOR), Luczak, A.A.4 (AUTHOR), Schmidt, H.2 (AUTHOR), Bastholt, L.3 (AUTHOR), Svane, I.M.1 (AUTHOR), Donia, M.1 (AUTHOR), Ellebaek, E.1 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS977-S978. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
